WO1998022824A1 - Immunochromatography test strips - Google Patents

Immunochromatography test strips Download PDF

Info

Publication number
WO1998022824A1
WO1998022824A1 PCT/IL1997/000377 IL9700377W WO9822824A1 WO 1998022824 A1 WO1998022824 A1 WO 1998022824A1 IL 9700377 W IL9700377 W IL 9700377W WO 9822824 A1 WO9822824 A1 WO 9822824A1
Authority
WO
WIPO (PCT)
Prior art keywords
test
analyte
membrane
zone
interest
Prior art date
Application number
PCT/IL1997/000377
Other languages
French (fr)
Inventor
Avraham Zer
Tamar Zer
Original Assignee
Avraham Zer
Tamar Zer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avraham Zer, Tamar Zer filed Critical Avraham Zer
Priority to AU49638/97A priority Critical patent/AU4963897A/en
Publication of WO1998022824A1 publication Critical patent/WO1998022824A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54386Analytical elements
    • G01N33/54387Immunochromatographic test strips
    • G01N33/54388Immunochromatographic test strips based on lateral flow
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody

Definitions

  • the invention relates to an analytical test strip for the detection of an analyte of interest present in a liquid sample, based on immunochromatography of the analyte.
  • immunoassay methods for detecting antibodies or antigens are known in the art. In principle, such methods are base on the binding of an antibody or antigen of interest to an immobilized specific antigen or antibody thereagainst, or any other biological agent capable of specifically conjugating therewith to form a complex, and detecting a specific signal, which indicates the formation of such complex.
  • Signals used may be radioisotopic signals (such as ⁇ H, H- ⁇ I, 57Co), enzymatic signals (such as horseradish peroxidase, alkaline phosphatase), luminescent signals (such as luminol or acridine) or immunochromatographic signals (such as colloidal gold or colored latex particles).
  • immunochromatography methods known in the art are based on conjugation of antigens or antibodies to the colored particles to form conjugates.
  • Antigens or antibodies, directed against the analyte of interest referred to as "capturers” are bound to a porous membrane, optionally fixed onto a solid support, at a specific line along the membrane, referred to as the test line.
  • a liquid sample containing the analyte of interest to be detected is applied to one end of the test strip which contains the colored particles. As a result, the sample and the colored particles migrate together along the porous membrane.
  • the sample contains the analyte of interest
  • such analyte when applied to the membrane, will conjugate to part of the colored particles and move along the porous membrane until reaching the test line containing the "capturers".
  • the analyte will conjugate with its "capturer", forming a complex which would not further migrate along the porous membrane, fixing thereto also part of the colored particles, thus producing a visible colored signal, usually a fixed line, indicating the presence of the analyte of interest in the liquid sample, a positive result.
  • Any unconjugated colored particles will continue to migrate along the porous membrane until reaching a control line, comprising, bound thereto, the analyte of interest already conjugated to its "capturer".
  • the particles will bind to the bound analyte and a visible control line will also appear.
  • the unconjugated colored particles will pass through the test line, until reaching the control line.
  • only the visible control line will appear. Since at the position of the test line no visible color has been formed, the appearance of only the single, control line will indicate a negative result.
  • Typical immunochromatographic tests for measuring antigen are for detection of Human Chorionic Gonadotropin (HCG) and Human Immunodeficiency Virus (HIV).
  • HCG Human Chorionic Gonadotropin
  • HIV Human Immunodeficiency Virus
  • the present invention relates to a test strip for detecting the presence of an analyte of interest in a biological liquid sample, said strip comprising a porous membrane suitably adhered to a solid support and having a first end and a second end; a matrix comprising labelled particles suitably fixed onto said first end of said porous membrane, said labelled particles capable of conjugating with said analyte of interest, upon contact therewith, to form a conjugate capable of migrating at least downstream along said membrane toward said second end when said membrane is in a wet state; at least one test zone delineated on said porous membrane downstream of said matrix, said at least one test zone comprising a first biological agent bound thereto capable of specifically conjugating with said analyte of interest, at least one control zone delineated on said membrane and located downstream of said matrix, said at least one control zone comprising a coloured material capable of being washed away from said control zone on contact with said liquid sample, as said liquid sample migrates across said control zone towards
  • test strip according to the invention may comprise a single test zone downstream of said matrix, or a plurality of test zones preferably, also downstream to said matrix.
  • said coloured material is chemically inert with respect to at least the analyte of interest, and said labelled particles are bound to a second biological agent.
  • the strip of the invention may be accommodated within a housing, said housing enabling at least part of said matrix to be in communication with the exterior of said housing such that said sample can be applied to said test strip, and further comprising a window juxtaposed over at least a portion of said strip, the said membrane located on said portion being in visual communication with the exterior of the housing, wherein said portion comprises at least a part of at least one said test zone and further comprises said at least control zone.
  • the invention is concerned with the different methods for detecting the presence of an analyte of interest in a biological liquid sample employing the test strip of the invention.
  • Figure 1 illustrates a perspective view of the first embodiment of the test strip according to the invention
  • Figure 2 illustrates a perspective view of the second embodiment of the test strip according to the invention
  • Figure 3a-3e illustrates a plan view of the test strip with different configurations of the test zones; (a) a single test zone being in the form of a narrow band; (b) a single test zone in the form of an elongated band; (c) a test strip comprising a plurality of test zones, each in the form of a narrow band and sequentially located adjacent one to another; (d) the test strip of Figure 3(c) comprising a low quantity of the analyte of interest, thus exhibiting only one signaled test zone; (e) the test strip of Figure 3(c) comprising a high quantity of the analyte of interest, thus exhibiting a plurality of signaled test zones.
  • Figure 4a-4b Figure 4(a) illustrates a plan view of one embodiment of a housing accommodating the test strip of Figure 2;
  • Figure 4(b) is a cross-sectional view along the line C-C of Fig. 4(a).
  • Figure 5a-5b Figure 5(a) illustrates a plan view of a different embodiment of a housing accommodating the test strip of Figure 2;
  • Figure 5(a) illustrates a plan view of a different embodiment of a housing accommodating the test strip of Figure 2;
  • FIG. 5(b) is a cross-sectional view along the line D-D of Fig. 5(a).
  • Figure 6a-6c Figure 6(a) illustrates a fragmented plan view of the housing showing the strip of Figure 3(b) via the window of the housing; Figure 6(b) illustrates schematically the manner in which a relatively low amount of analyte is detected; Figure 6(c) illustrates schematically the manner in which a relatively high amount of analyte is detected.
  • Figure 7(a) illustrates a fragmented plan view of the housing showing a strip, comprising a test zone in the form of a triangle, via the window of the housing;
  • Figures 7(b) to 7(d) illustrate schematically the manner in which positive results are indicated in relation to the appearance of the signaled triangle.
  • Figure 8a-8d Figure 8(a) illustrates a fragmented plan view of the housing showing the strip of Figure 3(c) via the window of the housing; Figure 8(b) illustrates a negative result; Figure 8(c) illustrates a positive result when a low amount of analyte is present in the sample; Figure 8(d) illustrates a positive result however when a high amount of analyte is present in the sample.
  • Figure 9(a) illustrates a fragmented plan view of the housing showing the strip of Figure 3(a), further comprising an auxiliary test zone, via the window of the housing;
  • Figure 10 illustrates a test strip comprising an extended support and an observation cover according to the third embodiment of the invention.
  • Figure lla-lle Figure 11(a) illustrates one example of a control zone as viewed through the observation cover of Figure 10;
  • FIG. 11(b) illustrates a negative result obtained with the strip of Figure 10
  • Figure 11(c), Figure 11(d) and Figure 11(e) illustrate positive results obtained with the strip of Figure 10 with a low, medium and high amount of analyte in the sample, respectively.
  • Figure 12 illustrates a perspective view of the fourth embodiment of the test strip according to the invention.
  • the present invention relates to a test strip for detecting the presence of an analyte of interest in a biological liquid sample, said strip comprising a porous membrane suitably adhered to a solid support and having a first end and a second end; a matrix comprising labelled particles suitably fixed onto said first end of said porous membrane, said labelled particles capable of conjugating with said analyte of interest, upon contact therewith, to form a conjugate capable of migrating at least downstream along said membrane toward, said second end when said membrane is in a wet state; at least one test zone delineated on said porous membrane downstream of said matrix, said at least one test zone comprising a first biological agent bound thereto capable of specifically conjugating to said analyte of interest, at least one control zone delineated on said membrane and located downstream of said matrix, said at least one control zone comprising a coloured material capable of being washed from said control zone on contact with said liquid sample, as said liquid sample migrates across said control zone towards said second end.
  • Figure 1 illustrates the first embodiment of a typical strip for detecting the presence of an analyte of interest in a biological liquid sample according the present invention.
  • the strip of the invention generally designated (10), comprises a porous membrane (30) suitably adhered to a solid support (20).
  • the strip (10) is typically elongate and conveniently rectangular, and comprises a first end, (12) and a second end, (14), wherein said first end is upstream to said second end.
  • the strip (10) is also preferably of a rectangular cross section, having a width greater than its depth.
  • said membrane is a cellulose or nitrocellulose membrane.
  • Cellulose membranes can be pretreated by various methods, for example by cyanogen bromide activation for photoactivation reagents. Further, the membrane can be further coated with a blocking reagent which is capable of preventing a false positive result.
  • a matrix (40), comprising labelled particles, is suitably fixed onto said first end (12) of said porous membrane (30).
  • Said labelled particles are capable of conjugating with an analyte of interest, upon contact therewith, to form a conjugate which is capable of migrating at least downstream along said membrane toward said second end (14) when said membrane (30) is in a wet state.
  • the said labelled particles are typically colloidal gold particles or alternatively coloured latex particles and are thus readily visible to the user.
  • the labelled particles are preferably bound to a second biological agent which may be a protein or a peptide, preferably protein A or an antibody directed against immunoglobulin A.
  • the labelled particles may be bound to other biological or chemical agents which in the presence of said analyte of interest may lead to the production of a detectable signal.
  • the said matrix (40) is typically comprised of fiber glass or polyester, or any other suitable material which does not prevent the labelled particles from migrating along the membrane (30) when the latter is in a wet state.
  • the test zone (50) of the invention is preferably delineated on said porous membrane (30) downstream of said matrix (40), and comprises a first biological agent, bound to said porous membrane in said test zone (50), which is capable of specifically conjugating with said analyte of interest.
  • the test zone may be in the form of a narrow band across substantially the width of said strip (10) and substantially orthogonal to the migration path of the liquid sample through the membrane (30). Nonetheless, other configurations of the test zone are possible, as is the delineation of a plurality of test zones on said strip (10), as hereinafter described for different embodiments of the present invention.
  • the test strip (10) further comprises at least one control zone (60) which is delineated on said membrane (30) and is typically located downstream of said matrix (40).
  • the control zone (60) is also located downstream of the said test zone (50), though the control zone (60) may alternatively be located upstream of the said test zone (50) or within it. Having said control zone within said test zone may be advantageous, for example because it enables the user to anticipate the zone in which a positive result signal, if any, would appear.
  • the control zone (60) comprises a coloured material capable of being washed away from said control zone (60) upon contact with said liquid sample, as said liquid sample migrates across said control zone towards said second end.
  • the said coloured material is chemically inert with respect to at least the analyte of interest.
  • 'inert' it is meant that the coloured material does not react with the analyte of interest and does not interfere with its capability to conjugate with said first biological agent in said test zone.
  • Said coloured material is typically a food dye, a blue cobalt salt or any other suitable chemically inert water-soluble marker.
  • the test strip (10) may be used as follows.
  • a biological or chemical liquid sample is brought into contact with the matrix (40) by pipetting the sample directly onto the membrane, for example, or alternatively by immersing at least a portion of the strip, preferably at the first end (12) of said strip (10), and more preferably at least including a portion of the matrix (30), in a quantity of the liquid sample which may be contained in a holding vessel.
  • the liquid sample is absorbed into the matrix (40) and from there into the membrane (30) (which as result becomes wet), together with said labelled particles which comprise said second biological agent.
  • the migration path of the liquid sample is generally parallel to the length of the strip.
  • the labelled particles will conjugate therewith to form a conjugate which migrates along said membrane, and which in turn conjugates with the said first biological agent bound to membrane in the test zone (50) and becomes immobilised.
  • the test zone (50) contains a signal produced by the analyte-labelled particles (with second biological agent)-first biological agent complex which is immobilised within said test zone, which signal is detectable by the user.
  • a typical signal would be the appearance of a colour at the said test zone (50).
  • the liquid sample together with the labelled particles, migrate downstream toward the said second end (14) of the strip (10), the coloured material comprised in the control zone is washed away, thereby conclusively indicating to the user that the strip is functioning normally. If the analyte of interest in not present in the sample, the labelled particles migrate together with the sample towards the second end (14), past the said one or more test zones (50).
  • FIG. 2 illustrates the strip (110) according to a second embodiment of the present invention.
  • the strip (110) comprises a porous membrane (130) on a backing (120), and a matrix (140), with at least one test zone (150) and a control zone (160), and is substantially similar to the strip (10) hereinbefore described in relation to the first embodiment, mutatis mutandis.
  • the strip (110) further comprises a first bibulous or spongy material (170), which may be pretreated with a suitable buffer solution suitably fixed onto at least said matrix., and optionally a second bibulous or spongy material (180) suitably fixed to said porous membrane downstream of said control zone and said test zone.
  • Said first spongy material may also be fixed onto part of said membrane (130), and may act as a reservoir for receiving the liquid sample and releasing it onto at least the matrix (130), and optionally also directly onto the membrane (130).
  • the second spongy material (180) may act as a reservoir to collect the liquid sample, together with washed-away coloured material and/or labelled particles after migration of the liquid sample through the said membrane (130), past the said control zone (160).
  • said first spongy material and said second spongy material is filter paper, and said buffer is PBS (phosphate buffered saline), borate buffer or any other suitable buffer.
  • PBS phosphate buffered saline
  • the said strip (110) may comprise a single test zone (150) downstream of said matrix (140), said test zone (150) being in the form of a narrow band (151) across substantially the width of said strip and substantially orthogonal to the migration path of said liquid sample on said membrane (130), as illustrated in Figure 3(a).
  • test zone configuration is useful for the qualitative detection of an analyte of interest in a liquid sample.
  • the single test zone (150) may be in the form of an elongate band (152) having a width substantially equal to the width of the said strip (110), and is illustrated in Figure 3(b).
  • a test zone configuration may give an indication to the user of the quantity of analyte in the sample: the greater the quantity of analyte, the larger the area of the test zone that is rendered detectable.
  • the development of a quantifiable signal in the test zone may be assessed with an appropriate form of instrumentation.
  • test strip (110) may comprise a plurality of test zones (150).
  • test zones (150) may be in the form of a narrow bands (153) across substantially the width of said strip (110), sequentially located, preferably adjacent one to another on said strip (110), as illustrated in Figure 3(c).
  • such a test zone configuration may give an indication to the user of the quantity of analyte in the sample in a digital-type display. The greater the quantity of analyte, the larger the number of bands (153) that are rendered visible.
  • Figures 3(d) and 3(e) illustrate schematically the manner in which positive results may be indicated on such a strip when analyte is present in the sample in relatively low and high quantities, respectively.
  • the strip (110) of the second embodiment may be used in a similar manner to that described for the strip (10) of the first embodiment, mutatis mutandis, with the difference that liquid sample may be absorbed into the matrix (140) via the first spongy material (170).
  • the strip (110) may be accommodated within a housing (100), said housing (100) enabling at least part of said matrix (140) to be in direct or indirect communication with the exterior of said housing (100) such that said sample can be applied to said test strip (110).
  • the said matrix (140) is in communication with the exterior (600) of said housing (100) via an inlet port (200) comprised therein, wherein said inlet port (200) enables said sample to be brought into contact with said matrix (140) via said first spongy material (170).
  • a sample of liquid may be pipetted onto said first spongy material (170) through said inlet port (200).
  • said matrix (140) is in communication with the exterior (600) of said housing (100) via a bibulous receiving member (500), as illustrated in Figure 5.
  • the receiving member (500) protrudes from said housing (100) via a suitable opening (550) upstream of said matrix (140) and is in communication therewith.
  • said receiving member (500) is an upstream extension of said membrane and support (120) past said first end (112), and may further comprise a parallel upstream extension of said first spongy material (170).
  • the receiving member (500) may act as a reservoir for receiving said liquid sample and releasing it onto at least said matrix (140).
  • a biological liquid sample is brought into contact with said receiving member (500) by immersing at least the upstream end of the same into a vessel comprising a quantity of said liquid sample.
  • said housing (100) comprises a hollow casing construction, and is made from a moisture impervious solid material such as a suitable plastic material, for example.
  • the housing (100) further comprises a window (300) juxtaposed over at least a portion (115) of said strip (110), so that the membrane (130) located on said portion (115) is in visual communication with the exterior (600) of the housing (100).
  • the said portion (115) comprises at least a part of at least one said test zone (150) and further comprises said control zone (160).
  • Said window is typically rectangular in form, preferably having a width slightly narrower than that of the strip (110).
  • the said casing (100) may further comprise a suitable scale (111) along at least one side of said window (100) parallel to the migration path of the liquid, as illustrated schematically in Figure 6(a).
  • the scale (111) may be calibrated to provide the user with a measure of quantity of analyte in the sample.
  • Figure 6(b) and 6(c) illustrate schematically the manner in which positive results may be indicated on such a strip when analyte is present in the sample in relatively low and high quantities, respectively.
  • the said strip (110) may comprise test zone (150) in the form of an elongate triangle (156) having its base at the downstream end of the window and its apex at the upstream thereof, as illustrated in Figure 7(a).
  • Figure 7(b) and 7(c) illustrate schematically the manner in which positive results may be indicated on such a strip when analyte is present in the sample in relatively low and high quantities, respectively.
  • the said strip (110) may comprise a plurality of test zones in the form of narrow bands (153), as illustrated schematically in Figure 8(a).
  • Figure 8(b) illustrates schematically a negative result for this arrangement
  • Figures 8(c) and 8(d) illustrate schematically the manner in which positive results may be indicated on such a strip when analyte is present in the sample in relatively low and high quantities, respectively.
  • a suitable scale may be provided on the said housing adjacent to the window (300), in a similar manner to scale (111) hereinbefore described.
  • said strip (110) further comprises at least one auxiliary test zone (157) upstream of said window (300) comprising said first biological agent in sufficient amount for conjugating with a quantity of said analyte in said sample up to a predetermined minimum quantity of said analyte.
  • auxiliary test zone 157) upstream of said window (300) comprising said first biological agent in sufficient amount for conjugating with a quantity of said analyte in said sample up to a predetermined minimum quantity of said analyte.
  • auxiliary test zone (157) is preferably obscured by the casing and the positive result on the auxiliary test zone (157) will thus not be visible to the user, as illustrated in Figure 9(b).
  • the first biological agent in said auxiliary test zone (157) is conjugated with said analyte to saturation, allowing the excess analyte to conjugate with said biological agent bound in said test zone (150) comprised within said portion (115), rendering the said test zone (150) at least partially detectable by the user, as illustrated in Figure 9(c).
  • the said housing (100) may alternatively accommodate the strip (10) of the said first embodiment in a similar manner to the second embodiment of the strip of the present invention, mutatis mutandis.
  • test strip (700) for detecting the presence of an analyte of interest comprises a porous membrane (730) suitably attached to a solid support (720) at a first end (712) thereof.
  • the said membrane (730) is typically in the form of a rectangle of low aspect ratio, having a width approximately the same as its length and is preferably a cellulose or nitrocellulose membrane.
  • the said support is typically of a width substantially similar to that of the membrane (730), but comprises a much greater length, such that the second end (714) of the support (720) is free of the membrane (730) and may be used as a handle by a user.
  • the strip (700) further comprises an observation cover (710), typically made from a suitable transparent material, suitably attached to the said membrane (730).
  • the cover (710) has substantially the same size and shape as the membrane (730) and is juxtaposed on the same.
  • the four edges (735) of the membrane (730) are thus left exposed.
  • a control zone (760) may be delineated on the said membrane (730), comprising a coloured material capable of being washed away by the liquid sample on contact therewith.
  • the control zone (760) may be in the form of a ring, for example, as illustrated in Figure 11(a), or in any other suitable form.
  • the strip (700) further comprises a test zone (750) delineated on the membrane (730) comprising a first biological agent bound thereto capable of specifically conjugating to said analyte of interest.
  • the test zone (750) extends across substantially the full width and length of the membrane (730), as illustrated in Figure 11(b).
  • the strip (700) of the present invention may be used as follows.
  • the said first end (712) of the strip (700) is immersed into a vessel containing the said biological liquid sample, previously mixed with labelled particles, so that the free edges (735) of the membrane (730) are swelled by the liquid mixture.
  • the strip may be immersed sequentially in two different vessels, one containing the liquid sample to be tested and the other containing the labelled particles in a suitable buffer solution.
  • the strip is then removed from the vessel(s).
  • the disappearance of the said colour from said control zone (760) indicates that the test is valid and that the strip was used properly, while there are no other detectable changes in the test zone (760), indicates a negative result.
  • Figures 11(c), 11(d) and 11(e) illustrate schematically the manner in which positive results may be indicated on such a strip when analyte is present in the sample in relatively low, medium and high quantities, respectively.
  • this embodiment is useful in determining the presence of analyte in both a quantitative and qualitative manner. 4th Embodiment
  • FIG 12 illustrates the fourth embodiment of a typical strip for detecting the presence of an analyte of interest in a biological liquid sample according the present invention.
  • the strip generally designated (800) comprises a porous membrane (830) suitably adhered to a solid support (820).
  • the strip (800) is typically elongate and conveniently rectangular, and comprises an first end (812) and a second end (814).
  • the strip (800) is also preferably of a rectangular cross section, having a width greater than its depth.
  • said membrane (830) is a cellulose or nitrocellulose membrane.
  • the said strip (800) comprises a test zone (850) of the invention is preferably delineated on said porous membrane (830) and comprises a first biological agent, bound in said test zone (850) to said porous membrane capable of specifically conjugating with said analyte of interest.
  • the test zone (850) is preferably in the form of an elongate band (852), though it may take other forms.
  • the strip (800) according to the invention further comprises at least one control zone (860) which is delineated on said membrane (830) and typically located downstream of the said test zone (850), though the control zone (860) may alternatively be located upstream of the said test zone (850) or within it.
  • the control zone (860) comprises a coloured material capable of being washed away from said control zone (860) upon contact with said liquid sample.
  • the said coloured material is chemically inert with respect to at least the analyte of interest, and said coloured material is typically a food dye, a blue cobalt salt or any other suitable chemically inert water-soluble marker.
  • the test strip (800) of the invention may be used as follows.
  • the said first end (812) of the strip (800) is immersed in a biological liquid sample contained in a vessel, previously mixed with labelled particles.
  • the strip may be immersed sequentially in the liquid sample to be tested contained in one vessel and in a buffer solution containing the labelled particles contained in another vessel in a suitable buffer solution.
  • the strip is then removed from the vessel(s).
  • the disappearance of the colour from the said control zone (860) indicates that the test is valid and that the strip was used properly, while there are no other detectable changes in the test zone (860), indicates a negative result. Whereas, with a positive result, a detectable signal, distinguishable from the coloured marker will appear in said test zone.
  • said labelled particles are preferably bound to a second biological agent, said second biological agent being a protein, a peptide. or an antibody directed against a human immunoglobulin.
  • the analyte of interest to be detected can be an antibody, such as antibodies directed against Human Immunodeficiency Virus 1 (HIV-1), Human Immunodeficiency Virus (HIV-2), Hepatitis B surface Antigen (HBsAG) or Hepatitis C Virus (HCV), such that the said first biological agent comprises antigens which specifically bind to said HIV-1, HIV-2, HBsAg or HCV antibodies, respectively.
  • HIV-1 Human Immunodeficiency Virus 1
  • HCV-2 Human Immunodeficiency Virus
  • HBsAG Hepatitis B surface Antigen
  • HCV Hepatitis C Virus
  • the analyte of interest can also be a hormone, such as, for example, Human Chorionic Gonadotropin (HCG), Luteinizing Stimulating Hormone (LH), Follicle Stimulating Hormone (FSH) or Thyroid Stimulating Hormone (TSH), and said first biological agent thus is preferably selected from antibodies which specifically bind to said HCG, LH, FSH or TSH, respectively.
  • HCG Human Chorionic Gonadotropin
  • LH Luteinizing Stimulating Hormone
  • FSH Follicle Stimulating Hormone
  • TSH Thyroid Stimulating Hormone
  • the analyte of interest may be CK-MB, prolactine, an opiate, THC or an amphetamine, and thus said first biological agent may comprise antibodies which specifically bind to said CK-MB, prolactine, opiate, THC or amphetamine, respectively.
  • the analyte of interest may be any other biological or chemical material.
  • proteins or peptides may be detected by the strip of the invention. Such proteins may be, for example, enzymes which are capable of conjugating with said labelled particles and with a suitable substrate at said test zone. The action of the enzyme on the substrate may give rise to the formation of a detectable signal.
  • the analyte of interest may also be a microorganism, such as, for example, a Salmonella sp., a Chlamydia sp., a Streptococcus hemoliticus group A (Strep- A) or Streptococcus hemoliticus group B (Strep-B), said test zone carries antibodies directed against said Salmonella sp., a Chlamydia sp., a Streptococcus hemoliticus group A (Strep-A) or Streptococcus hemoliticus group B (Strep-B), respectively, and said first biological agent may then comprise antibodies which specifically bind to said Salmonella sp., Chlamydia sp., Strep-A or Strep-B, respectively.
  • the analyte to be detected in said biological liquid sample is HCG.
  • the invention relates to a method for detecting the presence of an analyte of interest in a biological liquid sample comprising the steps of (a) providing a test strip comprising: (i) a porous membrane suitably adhered to a solid support; (ii) at least one test zone on said porous membrane comprising a first biological agent bound thereto, capable of specifically conjugating to said analyte of interest; (iii) at least one control zone delineated on said membrane, said at least one control zone comprising a coloured material capable of being washed away from said control zone on contact with said liquid sample; (b) bringing said biological liquid sample into contact with labelled particles bound to a second biological agent, said second biological agent being capable of conjugating with said analyte of interest, upon contact therewith; (c) immersing the test strip obtained in step (a) in the mixture obtained in step (b), such that said analyte of interest, if present in said biological liquid sample, specifically conjugates with said first biological agent
  • test strip for use in the above described method of the invention, is within the scope of the invention.
  • This test strip comprises a porous membrane suitably adhered to a solid support; at least one test zone on said porous membrane comprising a first biological agent bound thereto, capable of specifically conjugating with said analyte of interest; and at least one control zone delineated on said membrane, said at least one control zone comprising a coloured material capable of being washed away from said control zone upon contact with said liquid sample.
  • the invention provides a test strip for use in the method of the invention as hereinbefore described, which comprises a porous membrane suitably adhered to a solid support, said solid support substantially extending upstream from said membrane to provide a handle-like extension; a test zone on said porous membrane comprising a first biological agent bound thereto, capable of specifically conjugating with said analyte of interest; a control zone delineated on said membrane, said at least one control zone comprising a coloured material capable of being washed away from said control zone upon contact with said liquid sample, said test strip being characterized in that it further comprises a transparent, non-permeable, observation cover suitably attached onto said membrane, juxtaposed to said support, and having substantially the size and shape of said membrane.
  • the invention is concerned with a method of detecting the presence of an analyte of interest in a biological liquid sample by employing the test strip of the invention, said method comprising the steps of applying a sufficient amount of said biological liquid sample onto said matrix; allowing the liquid sample to migrate at least downstream along said membrane, towards said second end, and determining whether or not said analyte of interest is present in said biological liquid sample whereby the mere disappearance of said coloured material from the control zone indicates absence of said analyte from said sample while the disappearance of said coloured material from the control zone together with the appearance of a detectable signal in said test zone indicates the presence of said analyte of interest in said sample and the preservation of said coloured material in said control zone indicates improper use.
  • test strips of the invention may be prepared by a method comprising the following steps: adhering a porous membrane onto a solid support, applying said first biological agent (e.g. an antibody or antigen or any other biological agent which may specifically bind to said analyte of interest), preferably present in a buffer solution, onto said membrane, to form the test zone and drying the same, applying said coloured material onto said membrane to form said control zone, applying the labelled particles, preferably with said second biological agent bound thereto, to the matrix and fixing the same preferably to said first end of said porous membrane, and drying the same.
  • said first biological agent e.g. an antibody or antigen or any other biological agent which may specifically bind to said analyte of interest
  • the coloured control zone is necessary in order to determine whether the test was conducted properly.
  • additional advantages of having said coloured control zone may be found when the control zone is located within said test zone.
  • Such an integral zone may be obtained by mixing the coloured material and the first biological agent prior to application thereof onto said membrane.
  • One advantage obtained thereby, for example, is significant during the process for manufacturing said test strips, since only one application process onto said membrane is required, which evidently will enable to reduce machine "printing time" by about 50%. Nonetheless, an integral test zone and control zone will enable the user to easily anticipate the location of the signal produced when the test results are positive.
  • control zone acts also s a quality control footprint.
  • additional quality control means may be provided by printing additional control zones on said membrane, in other areas.
  • a second control zone may be applied to said membrane at the second end of said strip.
  • Such marker can easily indicate to which end of the test strip the liquid sample has to be applied, in case using the strip as such.
  • the strip is accommodated within a housing which has said inlet port, if this coloured signal is visible through said inlet port, it would indicate that the strip has been inserted into said housing in the wrong direction.
  • strip of the present invention over the known devices, usually accommodated within a housing and packed in moisture-proof packaging such as aluminum pouches, is that an accidental puncture of the packaging or production defects yielding incomplete sealing of said packaging or housing will result in a non-visible control zone.
  • use of hygroscopic colors for the control zone, as in the present invention will enable the indication of any exposure to humidity prior to use, since as a result of such exposure, the colour in the control zone will change, e.g. from blue in the dry form to brown in the hydrous form.
  • All the embodiments of the present invention can be used for quantitative measurements when required. Any suitable instruments, as known to the man skilled in the art, may be of use, depending on the type of the detectable signal obtained. The man skilled in the art would know, in accordance with the signal produced by the presence of said analyte of interest, which methods of analytical determinations and instruments to use.

Abstract

The invention relates to a method and test strip for detecting the presence of an analyte of interest in a biological liquid sample. The test strip comprises a porous membrane (30) adhered to a solid support (20) which has a first end (12) and a second end (14); a matrix (40) comprising labelled particles fixed to the first end of the membrane, which particles are capable of conjugating with an analyte of interest which may be present in the sample to form a conjugate which can migrate along the membrane toward the second end when the membrane is in a wet state and at least one test zone (50) on the membrane downstream of the matrix, which test zone comprises a first biological agent bound thereto which is capable of specifically conjugating with the analyte of interest, and at least one control zone (60) delineated on said membrane and located downstream of said matrix, which comprises a detectable marker capable of being washed away from the control zone on contact with said liquid sample, as said liquid sample migrates across said control zone towards said second end.

Description

IMMUNOCHROMATOGRAPHY TEST STRIPS
BACKGROUND OF THE INVENTION
The invention relates to an analytical test strip for the detection of an analyte of interest present in a liquid sample, based on immunochromatography of the analyte.
Several immunoassay methods for detecting antibodies or antigens are known in the art. In principle, such methods are base on the binding of an antibody or antigen of interest to an immobilized specific antigen or antibody thereagainst, or any other biological agent capable of specifically conjugating therewith to form a complex, and detecting a specific signal, which indicates the formation of such complex. Signals used may be radioisotopic signals (such as ^H, H-^I, 57Co), enzymatic signals (such as horseradish peroxidase, alkaline phosphatase), luminescent signals (such as luminol or acridine) or immunochromatographic signals (such as colloidal gold or colored latex particles).
More specifically, immunochromatography methods known in the art are based on conjugation of antigens or antibodies to the colored particles to form conjugates. Antigens or antibodies, directed against the analyte of interest, referred to as "capturers", are bound to a porous membrane, optionally fixed onto a solid support, at a specific line along the membrane, referred to as the test line. According to this methodology, a liquid sample containing the analyte of interest to be detected is applied to one end of the test strip which contains the colored particles. As a result, the sample and the colored particles migrate together along the porous membrane. In case the sample contains the analyte of interest, such analyte, when applied to the membrane, will conjugate to part of the colored particles and move along the porous membrane until reaching the test line containing the "capturers". The analyte will conjugate with its "capturer", forming a complex which would not further migrate along the porous membrane, fixing thereto also part of the colored particles, thus producing a visible colored signal, usually a fixed line, indicating the presence of the analyte of interest in the liquid sample, a positive result. Any unconjugated colored particles will continue to migrate along the porous membrane until reaching a control line, comprising, bound thereto, the analyte of interest already conjugated to its "capturer". As a result, the particles will bind to the bound analyte and a visible control line will also appear. In case the analyte of interest is absent from the tested sample, the unconjugated colored particles will pass through the test line, until reaching the control line. As a result, only the visible control line will appear. Since at the position of the test line no visible color has been formed, the appearance of only the single, control line will indicate a negative result.
Typical immunochromatographic tests for measuring antigen are for detection of Human Chorionic Gonadotropin (HCG) and Human Immunodeficiency Virus (HIV). In the latter, antibodies present in the sample, bound to protein A conjugate with colloidal gold and this conjugate will bind, in a positive test, to the HIV antigens, fixed onto the membrane in the test line.
SUMMARY OF THE INVENTION The present invention relates to a test strip for detecting the presence of an analyte of interest in a biological liquid sample, said strip comprising a porous membrane suitably adhered to a solid support and having a first end and a second end; a matrix comprising labelled particles suitably fixed onto said first end of said porous membrane, said labelled particles capable of conjugating with said analyte of interest, upon contact therewith, to form a conjugate capable of migrating at least downstream along said membrane toward said second end when said membrane is in a wet state; at least one test zone delineated on said porous membrane downstream of said matrix, said at least one test zone comprising a first biological agent bound thereto capable of specifically conjugating with said analyte of interest, at least one control zone delineated on said membrane and located downstream of said matrix, said at least one control zone comprising a coloured material capable of being washed away from said control zone on contact with said liquid sample, as said liquid sample migrates across said control zone towards said second end.
The test strip according to the invention may comprise a single test zone downstream of said matrix, or a plurality of test zones preferably, also downstream to said matrix.
Within the test strip of the invention, said coloured material is chemically inert with respect to at least the analyte of interest, and said labelled particles are bound to a second biological agent.
The strip of the invention may be accommodated within a housing, said housing enabling at least part of said matrix to be in communication with the exterior of said housing such that said sample can be applied to said test strip, and further comprising a window juxtaposed over at least a portion of said strip, the said membrane located on said portion being in visual communication with the exterior of the housing, wherein said portion comprises at least a part of at least one said test zone and further comprises said at least control zone.
In addition the invention is concerned with the different methods for detecting the presence of an analyte of interest in a biological liquid sample employing the test strip of the invention. BRIEF DESCRIPTION OF THE FIGURES
Figure 1 illustrates a perspective view of the first embodiment of the test strip according to the invention;
Figure 2 illustrates a perspective view of the second embodiment of the test strip according to the invention;
Figure 3a-3e illustrates a plan view of the test strip with different configurations of the test zones; (a) a single test zone being in the form of a narrow band; (b) a single test zone in the form of an elongated band; (c) a test strip comprising a plurality of test zones, each in the form of a narrow band and sequentially located adjacent one to another; (d) the test strip of Figure 3(c) comprising a low quantity of the analyte of interest, thus exhibiting only one signaled test zone; (e) the test strip of Figure 3(c) comprising a high quantity of the analyte of interest, thus exhibiting a plurality of signaled test zones.
Figure 4a-4b Figure 4(a) illustrates a plan view of one embodiment of a housing accommodating the test strip of Figure 2; Figure 4(b) is a cross-sectional view along the line C-C of Fig. 4(a).
Figure 5a-5b Figure 5(a) illustrates a plan view of a different embodiment of a housing accommodating the test strip of Figure 2; Figure
5(b) is a cross-sectional view along the line D-D of Fig. 5(a).
Figure 6a-6c Figure 6(a) illustrates a fragmented plan view of the housing showing the strip of Figure 3(b) via the window of the housing; Figure 6(b) illustrates schematically the manner in which a relatively low amount of analyte is detected; Figure 6(c) illustrates schematically the manner in which a relatively high amount of analyte is detected.
Figure 7a-7d Figure 7(a) illustrates a fragmented plan view of the housing showing a strip, comprising a test zone in the form of a triangle, via the window of the housing; Figures 7(b) to 7(d) illustrate schematically the manner in which positive results are indicated in relation to the appearance of the signaled triangle.
Figure 8a-8d Figure 8(a) illustrates a fragmented plan view of the housing showing the strip of Figure 3(c) via the window of the housing; Figure 8(b) illustrates a negative result; Figure 8(c) illustrates a positive result when a low amount of analyte is present in the sample; Figure 8(d) illustrates a positive result however when a high amount of analyte is present in the sample.
Figure 9a-9c Figure 9(a) illustrates a fragmented plan view of the housing showing the strip of Figure 3(a), further comprising an auxiliary test zone, via the window of the housing; Figure
9(b) illustrates a negative result; Figure(c) illustrates a positive result.
Figure 10 illustrates a test strip comprising an extended support and an observation cover according to the third embodiment of the invention.
Figure lla-lle Figure 11(a) illustrates one example of a control zone as viewed through the observation cover of Figure 10; Figure
11(b) illustrates a negative result obtained with the strip of Figure 10; Figure 11(c), Figure 11(d) and Figure 11(e) illustrate positive results obtained with the strip of Figure 10 with a low, medium and high amount of analyte in the sample, respectively.
Figure 12 illustrates a perspective view of the fourth embodiment of the test strip according to the invention;
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a test strip for detecting the presence of an analyte of interest in a biological liquid sample, said strip comprising a porous membrane suitably adhered to a solid support and having a first end and a second end; a matrix comprising labelled particles suitably fixed onto said first end of said porous membrane, said labelled particles capable of conjugating with said analyte of interest, upon contact therewith, to form a conjugate capable of migrating at least downstream along said membrane toward, said second end when said membrane is in a wet state; at least one test zone delineated on said porous membrane downstream of said matrix, said at least one test zone comprising a first biological agent bound thereto capable of specifically conjugating to said analyte of interest, at least one control zone delineated on said membrane and located downstream of said matrix, said at least one control zone comprising a coloured material capable of being washed from said control zone on contact with said liquid sample, as said liquid sample migrates across said control zone towards said second end.
By way of example only, some preferred embodiments of this invention are described hereinbelow in detail, with reference to the accompanying drawings.
1st Embodiment
Figure 1 illustrates the first embodiment of a typical strip for detecting the presence of an analyte of interest in a biological liquid sample according the present invention. According to this embodiment, the strip of the invention, generally designated (10), comprises a porous membrane (30) suitably adhered to a solid support (20). The strip (10) is typically elongate and conveniently rectangular, and comprises a first end, (12) and a second end, (14), wherein said first end is upstream to said second end. The strip (10) is also preferably of a rectangular cross section, having a width greater than its depth. Typically, said membrane is a cellulose or nitrocellulose membrane. Cellulose membranes can be pretreated by various methods, for example by cyanogen bromide activation for photoactivation reagents. Further, the membrane can be further coated with a blocking reagent which is capable of preventing a false positive result.
A matrix (40), comprising labelled particles, is suitably fixed onto said first end (12) of said porous membrane (30). Said labelled particles are capable of conjugating with an analyte of interest, upon contact therewith, to form a conjugate which is capable of migrating at least downstream along said membrane toward said second end (14) when said membrane (30) is in a wet state. The said labelled particles are typically colloidal gold particles or alternatively coloured latex particles and are thus readily visible to the user. The labelled particles are preferably bound to a second biological agent which may be a protein or a peptide, preferably protein A or an antibody directed against immunoglobulin A. Alternatively, the labelled particles may be bound to other biological or chemical agents which in the presence of said analyte of interest may lead to the production of a detectable signal. The said matrix (40) is typically comprised of fiber glass or polyester, or any other suitable material which does not prevent the labelled particles from migrating along the membrane (30) when the latter is in a wet state.
The test zone (50) of the invention is preferably delineated on said porous membrane (30) downstream of said matrix (40), and comprises a first biological agent, bound to said porous membrane in said test zone (50), which is capable of specifically conjugating with said analyte of interest. The test zone may be in the form of a narrow band across substantially the width of said strip (10) and substantially orthogonal to the migration path of the liquid sample through the membrane (30). Nonetheless, other configurations of the test zone are possible, as is the delineation of a plurality of test zones on said strip (10), as hereinafter described for different embodiments of the present invention.
The test strip (10) further comprises at least one control zone (60) which is delineated on said membrane (30) and is typically located downstream of said matrix (40). In this embodiment, the control zone (60) is also located downstream of the said test zone (50), though the control zone (60) may alternatively be located upstream of the said test zone (50) or within it. Having said control zone within said test zone may be advantageous, for example because it enables the user to anticipate the zone in which a positive result signal, if any, would appear. The control zone (60) comprises a coloured material capable of being washed away from said control zone (60) upon contact with said liquid sample, as said liquid sample migrates across said control zone towards said second end. The said coloured material is chemically inert with respect to at least the analyte of interest. By the term 'inert' it is meant that the coloured material does not react with the analyte of interest and does not interfere with its capability to conjugate with said first biological agent in said test zone. Said coloured material is typically a food dye, a blue cobalt salt or any other suitable chemically inert water-soluble marker.
The test strip (10) may be used as follows. A biological or chemical liquid sample is brought into contact with the matrix (40) by pipetting the sample directly onto the membrane, for example, or alternatively by immersing at least a portion of the strip, preferably at the first end (12) of said strip (10), and more preferably at least including a portion of the matrix (30), in a quantity of the liquid sample which may be contained in a holding vessel. The liquid sample is absorbed into the matrix (40) and from there into the membrane (30) (which as result becomes wet), together with said labelled particles which comprise said second biological agent. The migration path of the liquid sample is generally parallel to the length of the strip.
If the analyte of interest is present in the liquid sample, the labelled particles will conjugate therewith to form a conjugate which migrates along said membrane, and which in turn conjugates with the said first biological agent bound to membrane in the test zone (50) and becomes immobilised. As a result, the test zone (50) contains a signal produced by the analyte-labelled particles (with second biological agent)-first biological agent complex which is immobilised within said test zone, which signal is detectable by the user. A typical signal would be the appearance of a colour at the said test zone (50).
Thus, as the liquid sample, together with the labelled particles, migrate downstream toward the said second end (14) of the strip (10), the coloured material comprised in the control zone is washed away, thereby conclusively indicating to the user that the strip is functioning normally. If the analyte of interest in not present in the sample, the labelled particles migrate together with the sample towards the second end (14), past the said one or more test zones (50).
2nd Embodiment
Figure 2 illustrates the strip (110) according to a second embodiment of the present invention. The strip (110) comprises a porous membrane (130) on a backing (120), and a matrix (140), with at least one test zone (150) and a control zone (160), and is substantially similar to the strip (10) hereinbefore described in relation to the first embodiment, mutatis mutandis. In the second embodiment, the strip (110) further comprises a first bibulous or spongy material (170), which may be pretreated with a suitable buffer solution suitably fixed onto at least said matrix., and optionally a second bibulous or spongy material (180) suitably fixed to said porous membrane downstream of said control zone and said test zone. Said first spongy material may also be fixed onto part of said membrane (130), and may act as a reservoir for receiving the liquid sample and releasing it onto at least the matrix (130), and optionally also directly onto the membrane (130). The second spongy material (180) may act as a reservoir to collect the liquid sample, together with washed-away coloured material and/or labelled particles after migration of the liquid sample through the said membrane (130), past the said control zone (160).
Preferably, said first spongy material and said second spongy material is filter paper, and said buffer is PBS (phosphate buffered saline), borate buffer or any other suitable buffer.
The said strip (110) according to the second embodiment of the present invention may comprise a single test zone (150) downstream of said matrix (140), said test zone (150) being in the form of a narrow band (151) across substantially the width of said strip and substantially orthogonal to the migration path of said liquid sample on said membrane (130), as illustrated in Figure 3(a). In general, such a test zone configuration is useful for the qualitative detection of an analyte of interest in a liquid sample.
Alternatively, the single test zone (150) may be in the form of an elongate band (152) having a width substantially equal to the width of the said strip (110), and is illustrated in Figure 3(b). In general, such a test zone configuration may give an indication to the user of the quantity of analyte in the sample: the greater the quantity of analyte, the larger the area of the test zone that is rendered detectable.
In general, the development of a quantifiable signal in the test zone may be assessed with an appropriate form of instrumentation.
Alternatively, the test strip (110) may comprise a plurality of test zones (150). These test zones (150) may be in the form of a narrow bands (153) across substantially the width of said strip (110), sequentially located, preferably adjacent one to another on said strip (110), as illustrated in Figure 3(c). In general, such a test zone configuration may give an indication to the user of the quantity of analyte in the sample in a digital-type display. The greater the quantity of analyte, the larger the number of bands (153) that are rendered visible. Figures 3(d) and 3(e) illustrate schematically the manner in which positive results may be indicated on such a strip when analyte is present in the sample in relatively low and high quantities, respectively.
The strip (110) of the second embodiment may be used in a similar manner to that described for the strip (10) of the first embodiment, mutatis mutandis, with the difference that liquid sample may be absorbed into the matrix (140) via the first spongy material (170).
Optionally, the strip (110) may be accommodated within a housing (100), said housing (100) enabling at least part of said matrix (140) to be in direct or indirect communication with the exterior of said housing (100) such that said sample can be applied to said test strip (110). In one embodiment of the housing (100), illustrated in Figure 4, the said matrix (140) is in communication with the exterior (600) of said housing (100) via an inlet port (200) comprised therein, wherein said inlet port (200) enables said sample to be brought into contact with said matrix (140) via said first spongy material (170). Typically, a sample of liquid may be pipetted onto said first spongy material (170) through said inlet port (200). Alternatively, said matrix (140) is in communication with the exterior (600) of said housing (100) via a bibulous receiving member (500), as illustrated in Figure 5. The receiving member (500) protrudes from said housing (100) via a suitable opening (550) upstream of said matrix (140) and is in communication therewith. Typically, said receiving member (500) is an upstream extension of said membrane and support (120) past said first end (112), and may further comprise a parallel upstream extension of said first spongy material (170). The receiving member (500) may act as a reservoir for receiving said liquid sample and releasing it onto at least said matrix (140). Typically, a biological liquid sample is brought into contact with said receiving member (500) by immersing at least the upstream end of the same into a vessel comprising a quantity of said liquid sample.
Typically, said housing (100) comprises a hollow casing construction, and is made from a moisture impervious solid material such as a suitable plastic material, for example.
The housing (100) further comprises a window (300) juxtaposed over at least a portion (115) of said strip (110), so that the membrane (130) located on said portion (115) is in visual communication with the exterior (600) of the housing (100). The said portion (115) comprises at least a part of at least one said test zone (150) and further comprises said control zone (160). Said window is typically rectangular in form, preferably having a width slightly narrower than that of the strip (110).
When said strip (110) comprises a test zone (150) in the form of an elongate band (152) as hereinbefore described, the said casing (100) may further comprise a suitable scale (111) along at least one side of said window (100) parallel to the migration path of the liquid, as illustrated schematically in Figure 6(a). The scale (111) may be calibrated to provide the user with a measure of quantity of analyte in the sample. Figure 6(b) and 6(c) illustrate schematically the manner in which positive results may be indicated on such a strip when analyte is present in the sample in relatively low and high quantities, respectively.
Alternatively, the said strip (110) may comprise test zone (150) in the form of an elongate triangle (156) having its base at the downstream end of the window and its apex at the upstream thereof, as illustrated in Figure 7(a). Figure 7(b) and 7(c) illustrate schematically the manner in which positive results may be indicated on such a strip when analyte is present in the sample in relatively low and high quantities, respectively.
Alternatively, the said strip (110) may comprise a plurality of test zones in the form of narrow bands (153), as illustrated schematically in Figure 8(a). Figure 8(b) illustrates schematically a negative result for this arrangement, while Figures 8(c) and 8(d) illustrate schematically the manner in which positive results may be indicated on such a strip when analyte is present in the sample in relatively low and high quantities, respectively. Optionally, a suitable scale may be provided on the said housing adjacent to the window (300), in a similar manner to scale (111) hereinbefore described.
Alternatively, and with reference to Figure 9(a), said strip (110) further comprises at least one auxiliary test zone (157) upstream of said window (300) comprising said first biological agent in sufficient amount for conjugating with a quantity of said analyte in said sample up to a predetermined minimum quantity of said analyte. Thus if a liquid sample contains the analyte of interest in quantities equal to or lower than said minimum quantity, all of the analyte will conjugate with the said first biological agent (bound to said labelled particles), bound to said auxiliary test zone (157). In such circumstances, a negative result will be indicated to the user, since the auxiliary test zone (157) is preferably obscured by the casing and the positive result on the auxiliary test zone (157) will thus not be visible to the user, as illustrated in Figure 9(b). When the analyte of interest is present in said sample in quantities in excess of said minimum quantity, the first biological agent in said auxiliary test zone (157) is conjugated with said analyte to saturation, allowing the excess analyte to conjugate with said biological agent bound in said test zone (150) comprised within said portion (115), rendering the said test zone (150) at least partially detectable by the user, as illustrated in Figure 9(c). In this manner, it is possible to calibrate the quantity of first biological agent in said auxiliary testy zone (157) for tests where only the detection of quantities of analyte greater than a predetermined minimum quantity is of interest to the user.
The said housing (100), may alternatively accommodate the strip (10) of the said first embodiment in a similar manner to the second embodiment of the strip of the present invention, mutatis mutandis.
3rd Embodiment
A third embodiment of the present invention is illustrated in Figure 10. In this embodiment the test strip (700) for detecting the presence of an analyte of interest according to the present invention comprises a porous membrane (730) suitably attached to a solid support (720) at a first end (712) thereof. The said membrane (730) is typically in the form of a rectangle of low aspect ratio, having a width approximately the same as its length and is preferably a cellulose or nitrocellulose membrane. The said support is typically of a width substantially similar to that of the membrane (730), but comprises a much greater length, such that the second end (714) of the support (720) is free of the membrane (730) and may be used as a handle by a user. The strip (700) further comprises an observation cover (710), typically made from a suitable transparent material, suitably attached to the said membrane (730). In this embodiment, the cover (710) has substantially the same size and shape as the membrane (730) and is juxtaposed on the same. The four edges (735) of the membrane (730) are thus left exposed. A control zone (760) may be delineated on the said membrane (730), comprising a coloured material capable of being washed away by the liquid sample on contact therewith. The control zone (760) may be in the form of a ring, for example, as illustrated in Figure 11(a), or in any other suitable form. The strip (700) further comprises a test zone (750) delineated on the membrane (730) comprising a first biological agent bound thereto capable of specifically conjugating to said analyte of interest. In this embodiment the test zone (750) extends across substantially the full width and length of the membrane (730), as illustrated in Figure 11(b).
The strip (700) of the present invention may be used as follows. The said first end (712) of the strip (700) is immersed into a vessel containing the said biological liquid sample, previously mixed with labelled particles, so that the free edges (735) of the membrane (730) are swelled by the liquid mixture. Alternatively, the strip may be immersed sequentially in two different vessels, one containing the liquid sample to be tested and the other containing the labelled particles in a suitable buffer solution. The strip is then removed from the vessel(s). The disappearance of the said colour from said control zone (760) indicates that the test is valid and that the strip was used properly, while there are no other detectable changes in the test zone (760), indicates a negative result. Figures 11(c), 11(d) and 11(e) illustrate schematically the manner in which positive results may be indicated on such a strip when analyte is present in the sample in relatively low, medium and high quantities, respectively. Thus, this embodiment is useful in determining the presence of analyte in both a quantitative and qualitative manner. 4th Embodiment
Figure 12 illustrates the fourth embodiment of a typical strip for detecting the presence of an analyte of interest in a biological liquid sample according the present invention. The strip, generally designated (800) comprises a porous membrane (830) suitably adhered to a solid support (820). The strip (800) is typically elongate and conveniently rectangular, and comprises an first end (812) and a second end (814). The strip (800) is also preferably of a rectangular cross section, having a width greater than its depth. Typically, said membrane (830) is a cellulose or nitrocellulose membrane.
The said strip (800) comprises a test zone (850) of the invention is preferably delineated on said porous membrane (830) and comprises a first biological agent, bound in said test zone (850) to said porous membrane capable of specifically conjugating with said analyte of interest. The test zone (850) is preferably in the form of an elongate band (852), though it may take other forms.
The strip (800) according to the invention further comprises at least one control zone (860) which is delineated on said membrane (830) and typically located downstream of the said test zone (850), though the control zone (860) may alternatively be located upstream of the said test zone (850) or within it. The control zone (860) comprises a coloured material capable of being washed away from said control zone (860) upon contact with said liquid sample. The said coloured material is chemically inert with respect to at least the analyte of interest, and said coloured material is typically a food dye, a blue cobalt salt or any other suitable chemically inert water-soluble marker.
The test strip (800) of the invention may be used as follows. The said first end (812) of the strip (800) is immersed in a biological liquid sample contained in a vessel, previously mixed with labelled particles. Alternatively, the strip may be immersed sequentially in the liquid sample to be tested contained in one vessel and in a buffer solution containing the labelled particles contained in another vessel in a suitable buffer solution. The strip is then removed from the vessel(s). The disappearance of the colour from the said control zone (860) indicates that the test is valid and that the strip was used properly, while there are no other detectable changes in the test zone (860), indicates a negative result. Whereas, with a positive result, a detectable signal, distinguishable from the coloured marker will appear in said test zone.
According to the present invention, and within the preferred embodiments as hereinbefore described, said labelled particles are preferably bound to a second biological agent, said second biological agent being a protein, a peptide. or an antibody directed against a human immunoglobulin.
The analyte of interest to be detected can be an antibody, such as antibodies directed against Human Immunodeficiency Virus 1 (HIV-1), Human Immunodeficiency Virus (HIV-2), Hepatitis B surface Antigen (HBsAG) or Hepatitis C Virus (HCV), such that the said first biological agent comprises antigens which specifically bind to said HIV-1, HIV-2, HBsAg or HCV antibodies, respectively.
The analyte of interest can also be a hormone, such as, for example, Human Chorionic Gonadotropin (HCG), Luteinizing Stimulating Hormone (LH), Follicle Stimulating Hormone (FSH) or Thyroid Stimulating Hormone (TSH), and said first biological agent thus is preferably selected from antibodies which specifically bind to said HCG, LH, FSH or TSH, respectively.
Further, the analyte of interest may be CK-MB, prolactine, an opiate, THC or an amphetamine, and thus said first biological agent may comprise antibodies which specifically bind to said CK-MB, prolactine, opiate, THC or amphetamine, respectively. Further, the analyte of interest may be any other biological or chemical material. Thus, other proteins or peptides may be detected by the strip of the invention. Such proteins may be, for example, enzymes which are capable of conjugating with said labelled particles and with a suitable substrate at said test zone. The action of the enzyme on the substrate may give rise to the formation of a detectable signal.
The analyte of interest may also be a microorganism, such as, for example, a Salmonella sp., a Chlamydia sp., a Streptococcus hemoliticus group A (Strep- A) or Streptococcus hemoliticus group B (Strep-B), said test zone carries antibodies directed against said Salmonella sp., a Chlamydia sp., a Streptococcus hemoliticus group A (Strep-A) or Streptococcus hemoliticus group B (Strep-B), respectively, and said first biological agent may then comprise antibodies which specifically bind to said Salmonella sp., Chlamydia sp., Strep-A or Strep-B, respectively.
Of particular interest, but not limited thereto, the analyte to be detected in said biological liquid sample is HCG.
In a different aspect, the invention relates to a method for detecting the presence of an analyte of interest in a biological liquid sample comprising the steps of (a) providing a test strip comprising: (i) a porous membrane suitably adhered to a solid support; (ii) at least one test zone on said porous membrane comprising a first biological agent bound thereto, capable of specifically conjugating to said analyte of interest; (iii) at least one control zone delineated on said membrane, said at least one control zone comprising a coloured material capable of being washed away from said control zone on contact with said liquid sample; (b) bringing said biological liquid sample into contact with labelled particles bound to a second biological agent, said second biological agent being capable of conjugating with said analyte of interest, upon contact therewith; (c) immersing the test strip obtained in step (a) in the mixture obtained in step (b), such that said analyte of interest, if present in said biological liquid sample, specifically conjugates with said first biological agent; whereby the mere disappearance of said coloured material from the control zone indicates the absence of said analyte from said sample and the disappearance of said coloured material from the control zone together with the appearance of a detectable signal indicative of the presence of said labelled particles in said test zone indicates the presence of analyte in said sample.
Further, a test strip for use in the above described method of the invention, is within the scope of the invention. This test strip comprises a porous membrane suitably adhered to a solid support; at least one test zone on said porous membrane comprising a first biological agent bound thereto, capable of specifically conjugating with said analyte of interest; and at least one control zone delineated on said membrane, said at least one control zone comprising a coloured material capable of being washed away from said control zone upon contact with said liquid sample.
In an additional embodiment, the invention provides a test strip for use in the method of the invention as hereinbefore described, which comprises a porous membrane suitably adhered to a solid support, said solid support substantially extending upstream from said membrane to provide a handle-like extension; a test zone on said porous membrane comprising a first biological agent bound thereto, capable of specifically conjugating with said analyte of interest; a control zone delineated on said membrane, said at least one control zone comprising a coloured material capable of being washed away from said control zone upon contact with said liquid sample, said test strip being characterized in that it further comprises a transparent, non-permeable, observation cover suitably attached onto said membrane, juxtaposed to said support, and having substantially the size and shape of said membrane. Finally the invention is concerned with a method of detecting the presence of an analyte of interest in a biological liquid sample by employing the test strip of the invention, said method comprising the steps of applying a sufficient amount of said biological liquid sample onto said matrix; allowing the liquid sample to migrate at least downstream along said membrane, towards said second end, and determining whether or not said analyte of interest is present in said biological liquid sample whereby the mere disappearance of said coloured material from the control zone indicates absence of said analyte from said sample while the disappearance of said coloured material from the control zone together with the appearance of a detectable signal in said test zone indicates the presence of said analyte of interest in said sample and the preservation of said coloured material in said control zone indicates improper use.
The test strips of the invention may be prepared by a method comprising the following steps: adhering a porous membrane onto a solid support, applying said first biological agent (e.g. an antibody or antigen or any other biological agent which may specifically bind to said analyte of interest), preferably present in a buffer solution, onto said membrane, to form the test zone and drying the same, applying said coloured material onto said membrane to form said control zone, applying the labelled particles, preferably with said second biological agent bound thereto, to the matrix and fixing the same preferably to said first end of said porous membrane, and drying the same.
As already noted above, the coloured control zone is necessary in order to determine whether the test was conducted properly. There are, nevertheless, additional advantages of having said coloured control zone, over the test strips known in the prior art, may be found when the control zone is located within said test zone. Such an integral zone may be obtained by mixing the coloured material and the first biological agent prior to application thereof onto said membrane. One advantage obtained thereby, for example, is significant during the process for manufacturing said test strips, since only one application process onto said membrane is required, which evidently will enable to reduce machine "printing time" by about 50%. Nonetheless, an integral test zone and control zone will enable the user to easily anticipate the location of the signal produced when the test results are positive.
In addition, the application of a mixture of a coloured material, acting as the control, with the first biological agent, will ensure the manufacturer, simply by eyesight, that the biological agent has been applied to said membrane, and thus, that the product is in integrity. Therefore, the control zone acts also s a quality control footprint.
Naturally, additional quality control means, may be provided by printing additional control zones on said membrane, in other areas. For example, a second control zone may be applied to said membrane at the second end of said strip. Such marker can easily indicate to which end of the test strip the liquid sample has to be applied, in case using the strip as such. In case the strip is accommodated within a housing which has said inlet port, if this coloured signal is visible through said inlet port, it would indicate that the strip has been inserted into said housing in the wrong direction.
Another advantage of the strip of the present invention over the known devices, usually accommodated within a housing and packed in moisture-proof packaging such as aluminum pouches, is that an accidental puncture of the packaging or production defects yielding incomplete sealing of said packaging or housing will result in a non-visible control zone. Thus, use of hygroscopic colors for the control zone, as in the present invention, will enable the indication of any exposure to humidity prior to use, since as a result of such exposure, the colour in the control zone will change, e.g. from blue in the dry form to brown in the hydrous form.
All the embodiments of the present invention can be used for quantitative measurements when required. Any suitable instruments, as known to the man skilled in the art, may be of use, depending on the type of the detectable signal obtained. The man skilled in the art would know, in accordance with the signal produced by the presence of said analyte of interest, which methods of analytical determinations and instruments to use.

Claims

CLAIMS:
1. A test strip for detecting the presence of an analyte of interest in a biological liquid sample, said strip comprising:
- a porous membrane suitably adhered to a solid support and having a first end and a second end;
- a matrix comprising labelled particles suitably fixed onto said first end of said porous membrane, said labelled particles capable of conjugating with said analyte of interest, upon contact therewith, to form a conjugate capable of migrating at least downstream along said membrane toward said second end when said membrane is in a wet state;
- at least one test zone delineated on said porous membrane downstream of said matrix, said at least one test zone comprising a first biological agent bound thereto capable of specifically conjugating with said analyte of interest,
- at least one control zone delineated on said membrane and located downstream of said matrix, said at least one control zone comprising a coloured material capable of being washed away from said control zone on contact with said liquid sample, as said liquid sample migrates across said control zone towards said second end.
2. The test strip according to claim 1 further comprising a first spongy material which may be pretreated with a suitable buffer solution suitably fixed onto at least said matrix.
3. The test strip according to claim 1 or 2 further comprising a second spongy material suitably fixed to said porous membrane downstream of said control zone and said test zone.
4. The strip according to claim 2 wherein said first spongy material is filter paper.
5. The strip according to claim 3 wherein said second spongy material is filter paper.
6. The test strip according to any one of claims 2 to 5 wherein said buffer is PBS, borate buffer or any other suitable buffer.
7. The test strip according to any of the preceding claims comprising a single test zone downstream to said matrix, said test zone being in the form of a narrow band across substantially the width of said strip and substantially orthogonal to the migration path of said liquid sample on said membrane.
8. The test strip according to any of claims 1 to 6 comprising a single test zone downstream of said matrix, said test zone being in the form of an elongate band having a width substantially equal to the width of the said strip.
9. The test strip according to any of claims 1 to 7 comprising a plurality of test zones.
10. The test strip according to claim 9 wherein said plurality of test zones are sequentially located adjacent one to another on said strip.
11. The test strip according to any of the preceding claims wherein said porous membrane is a cellulose or nitrocellulose membrane.
12. The test strip of claim 1 wherein said control zone is located within said test zone.
13. The test strip according to claim 1 wherein said control zone is located upstream of said test zone.
14. The test strip according to claim 1 wherein said control zone is located downstream of said test zone.
15. The test strip according to any of the preceding claims wherein said labelled particles comprise colloidal gold particles or coloured latex particles.
16. The strip according to any of the preceding claims wherein said matrix is comprised of fiber glass, polyester or any other suitable material which does not prevent said labelled particles from migrating along the membrane when said membrane is in a wet state.
17. The test strip according to any of the preceding claims wherein said coloured material is chemically inert with respect to at least the analyte of interest, said coloured material being a food dye, a blue cobalt salt or any other suitable chemically inert water-soluble marker.
18. The test strip according to any of the preceding claims wherein said labelled particles are bound to a second biological agent, said second biological agent being a peptide or a protein.
19. The test strip according to any of the preceding claims wherein said analyte of interest is:
- an antibody, preferably an antibody directed against Human Immunodeficiency Virus 1 (HIV-1), Human Immunodeficiency Virus (HIV-2), Hepatitis B surface Antigen (HBsAG) or Hepatitis C Virus (HCV), wherein said first biological agent comprises antigens which specifically bind to said HIV-1, HIV-2, HBsAg or HCV antibodies, respectively;
- a hormone, preferably Human Chorionic Gonadotropin (HCG), Luteinizing Stimulating Hormone (LH), Follicle Stimulating Hormone (FSH) or Thyroid Stimulating Hormone (TSH), wherein said first biological agent comprises antibodies which specifically bind to said HCG, LH, FSH or TSH, respectively;
- CK-MB, prolactine, an opiate, THC or an amphetamine, wherein said first biological agent comprises antibodies which specifically bind to said CK-MB, prolactine, opiate, THC or amphetamine, respectively; or
- a microorganism, preferably Salmonella sp., a Chlamydia sp., a Streptococcus hemoliticus group A (Strep-A) or Streptococcus hemoliticus group B (Strep-B), said test zone carries antibodies directed against said Salmonella sp., a Chlamydia sp., a Streptococcus hemoliticus group A (Strep-A) or Streptococcus hemoliticus group B (Strep-B), respectively, wherein said first biological agent comprises antibodies which specifically bind to said Salmonella sp., Chlamydia sp., Strep-A or Strep-B, respectively.
20. The test strip according to any of claims 1 to 19, accommodated within a housing, said housing enabling at least part of said matrix to be in communication with the exterior of said housing such that said sample can be applied to said test strip, and further comprising a window juxtaposed over at least a portion of said strip, the said membrane located on said portion being in visual communication with the exterior of the housing, wherein said portion comprises at least a part of at least one said test zone and further comprises said at least control zone.
21. The test strip according to claim 20, wherein said strip comprises at least one test zone upstream of said window for conjugating with a quantity of said analyte in said sample up to a predetermined minimum quantity of said analyte, whereby only quantities of analyte in said sample in excess of said minimum quantity are rendered visible via said window by virtue of further conjugation of said excess quantity of analyte with said biological agent comprised in a test zone comprised within said portion.
22. The test strip according to claims 20 or 21 wherein said matrix is in communication with the exterior of said housing via an inlet port comprised in said housing, wherein said inlet port enables said sample to be brought into contact with said matrix.
23. The test strip of claims 20 or 21 wherein said matrix is in communication with the exterior of said housing via a bibulous receiving member which protrudes from said housing upstream of said matrix and is in communication therewith, wherein said receiving member may act as a reservoir for receiving said liquid sample and releasing it onto at least said matrix, said receiving member may be immersed into a vessel comprising a quantity of said liquid sample.
24. A method for detecting the presence of an analyte of interest in a biological liquid sample comprising the steps of:
- providing a test strip comprising:-
- a porous membrane suitably adhered to a solid support;
- at least one test zone on said porous membrane comprising a first biological agent bound thereto, capable of specifically conjugating with said analyte of interest;
- at least one control zone delineated on said membrane, said at least one control zone comprising a coloured material capable of being washed away from said control zone upon contact with said liquid sample;
- bringing said biological liquid sample into contact with labelled particles bound to a second biological agent to form a mixture, said second biological agent capable of conjugating with said analyte of interest, upon contact therewith;
- immersing the test strip obtained in step (a) in the mixture obtained by step (b), such that said analyte of interest, if present in said biological liquid sample, specifically conjugates with said first biological agent; whereby:
- mere disappearance of said coloured material from said control zone indicates the absence of said analyte of interest from said sample; and
- disappearance of said coloured material from said control zone together with the appearance of a detectable signal indicative of the presence of said labelled particles in said test zone indicates the presence of said analyte of interest in said sample.
25. A test strip for use in the method of claim 23, said test strip comprising:
- a porous membrane suitably adhered to a solid support; - at least one test zone on said porous membrane comprising a first biological agent bound thereto, said first biological agent being capable of specifically conjugating with said analyte of interest;
- at least one control zone delineated on said membrane, said at least one control zone comprising a coloured material capable of being washed away from said control zone upon contact with said liquid sample.
26. A test strip for use in the method of claim 24, said test strip comprising:
- a porous membrane suitably adhered to a solid support, said solid support substantially extending upstream from said membrane to provide a handle-like extension;
- a test zone on said porous membrane comprising a first biological agent bound thereto, capable of specifically conjugating with said analyte of interest;
- a control zone delineated on said membrane, said at least one control zone comprising a coloured material capable of being washed away from said control zone upon contact with said liquid sample; said test strip being characterized in that it further comprises a transparent, non-permeable, observation cover suitably attached onto said membrane, juxtaposed to said support, and having substantially the size and shape of said membrane.
27. A method of detecting the presence of an analyte of interest in a biological liquid sample by ernploying a test strip according to claim 1 comprising the steps of:
- applying a sufficient amount of said biological liquid sample onto said matrix, and allowing the liquid sample to migrate at least downstream along said membrane, towards said second end,
- determining whether or not said analyte of interest is present in said biological liquid sample whereby: - mere disappearance of said coloured material from the control zone indicates absence of said analyte from said sample;
- disappearance of said coloured material from the control zone together with the appearance of a detectable signal in said test zone indicates the presence of said analyte of interest in said sample; and
- preservation of said coloured material in said control zone indicates improper use.
28. A method according to claim 27 or 30 for the detection of HCG in a liquid biological sample.
PCT/IL1997/000377 1996-11-18 1997-11-18 Immunochromatography test strips WO1998022824A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49638/97A AU4963897A (en) 1996-11-18 1997-11-18 Immunochromatography test strips

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3103096P 1996-11-18 1996-11-18
US60/031,030 1996-11-18

Publications (1)

Publication Number Publication Date
WO1998022824A1 true WO1998022824A1 (en) 1998-05-28

Family

ID=21857281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL1997/000377 WO1998022824A1 (en) 1996-11-18 1997-11-18 Immunochromatography test strips

Country Status (2)

Country Link
AU (1) AU4963897A (en)
WO (1) WO1998022824A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010013A2 (en) * 1998-08-14 2000-02-24 Biocontrol Systems, Inc. Composition and methods for exposing antigenic epitopes on cultered microorganism
EP1023600A1 (en) * 1998-07-29 2000-08-02 Syntron Bioresearch, Inc. Immunoassay device
WO2002065128A2 (en) * 2001-02-15 2002-08-22 Genosis Limited Urine assay for ovarian reserve
WO2003029813A2 (en) * 2001-09-25 2003-04-10 Prionics Ag Test strips for the detection of prion proteins
US6627057B1 (en) 1999-12-23 2003-09-30 Roche Diagnostic Corporation Microsphere containing sensor
EP1376131A1 (en) * 2002-06-27 2004-01-02 Inverness Medical Switzerland GmbH Assay device for liquid sample
EP1416275A1 (en) * 2002-10-31 2004-05-06 Oy Reagena Ltd Method for rapid test and control device
AU773650B2 (en) * 1998-08-14 2004-05-27 Biocontrol Systems, Incorporated Composition, formulae, devices and methods for control of specificity and inclusivity of microorganisms containing closely related antigen epitopes
WO2004058823A1 (en) * 2002-12-27 2004-07-15 Neobiodigm Co., Ltd Monoclonal antibody against asialo alpha 1-acid glycoprotein, immunochromatographic strip comprising the monoclonal antibody, and method for diagnosing liver diseases using the immunochromatographic strip
WO2006058610A1 (en) * 2004-12-01 2006-06-08 The Jordanian Pharmaceutical Manufacturing Co. Lateral-flow test device providing improved test result validity
WO2007122403A1 (en) * 2006-04-21 2007-11-01 British Pregnancy Advisory Service Device and method for detection of a pregnancy associated hormone
US7297502B2 (en) * 2004-12-17 2007-11-20 Oakville Hong Kong Company Limited Devices and methods for analyte assays with built-in result reporting using recognizable symbols
WO2007149043A1 (en) * 2006-06-20 2007-12-27 Åmic AB Assay device
CN101427137B (en) * 2006-04-21 2012-08-29 英国孕育咨询服务公司 Device and method for detection of a pregnancy associated hormone
AT512119A1 (en) * 2011-10-24 2013-05-15 Scheuringer Kim TEST DEVICE
WO2014134033A1 (en) 2013-02-26 2014-09-04 Astute Medical, Inc. Lateral flow assay with test strip retainer

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943522A (en) * 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5260194A (en) * 1986-09-05 1993-11-09 Syntex (U.S.A.) Inc. Immunoseparating strip
US5308775A (en) * 1992-09-15 1994-05-03 Abbott Laboratories Assay devices for concurrently detecting an analyte and confirming the test result
US5354692A (en) * 1992-09-08 1994-10-11 Pacific Biotech, Inc. Analyte detection device including a hydrophobic barrier for improved fluid flow
US5384264A (en) * 1992-11-05 1995-01-24 Syntron Bioresearch, Inc. Method and apparatus for single step assays of ligand-containing fluids
US5424220A (en) * 1992-01-31 1995-06-13 Boehringer Mannheim Gmbh Analysis element and method for determination of an analyte in a liquid sample
US5468648A (en) * 1991-05-29 1995-11-21 Smithkline Diagnostics, Inc. Interrupted-flow assay device
US5559041A (en) * 1989-12-18 1996-09-24 Princeton Biomeditech Corporation Immunoassay devices and materials
US5658801A (en) * 1994-05-03 1997-08-19 Spectral Diagnostics Inc. Medical test kit

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260194A (en) * 1986-09-05 1993-11-09 Syntex (U.S.A.) Inc. Immunoseparating strip
US4943522A (en) * 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5559041A (en) * 1989-12-18 1996-09-24 Princeton Biomeditech Corporation Immunoassay devices and materials
US5468648A (en) * 1991-05-29 1995-11-21 Smithkline Diagnostics, Inc. Interrupted-flow assay device
US5424220A (en) * 1992-01-31 1995-06-13 Boehringer Mannheim Gmbh Analysis element and method for determination of an analyte in a liquid sample
US5354692A (en) * 1992-09-08 1994-10-11 Pacific Biotech, Inc. Analyte detection device including a hydrophobic barrier for improved fluid flow
US5308775A (en) * 1992-09-15 1994-05-03 Abbott Laboratories Assay devices for concurrently detecting an analyte and confirming the test result
US5384264A (en) * 1992-11-05 1995-01-24 Syntron Bioresearch, Inc. Method and apparatus for single step assays of ligand-containing fluids
US5658801A (en) * 1994-05-03 1997-08-19 Spectral Diagnostics Inc. Medical test kit

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1023600A1 (en) * 1998-07-29 2000-08-02 Syntron Bioresearch, Inc. Immunoassay device
EP1023600A4 (en) * 1998-07-29 2002-05-08 Syntron Biores Inc Immunoassay device
WO2000010013A3 (en) * 1998-08-14 2000-06-22 Biocontrol Systems Inc Composition and methods for exposing antigenic epitopes on cultered microorganism
US6379918B1 (en) 1998-08-14 2002-04-30 Biocontrol Systems, Inc. Composition, formulae, devices and methods for control of specificity and inclusivity of microorganisms containing closely related antigen epitopes
WO2000010013A2 (en) * 1998-08-14 2000-02-24 Biocontrol Systems, Inc. Composition and methods for exposing antigenic epitopes on cultered microorganism
AU773650B2 (en) * 1998-08-14 2004-05-27 Biocontrol Systems, Incorporated Composition, formulae, devices and methods for control of specificity and inclusivity of microorganisms containing closely related antigen epitopes
US6627057B1 (en) 1999-12-23 2003-09-30 Roche Diagnostic Corporation Microsphere containing sensor
WO2002065128A3 (en) * 2001-02-15 2003-03-06 Genosis Ltd Urine assay for ovarian reserve
US7326578B2 (en) 2001-02-15 2008-02-05 Genosis (Uk) Limited Urine assay for ovarian reserve
WO2002065128A2 (en) * 2001-02-15 2002-08-22 Genosis Limited Urine assay for ovarian reserve
WO2003029813A3 (en) * 2001-09-25 2004-02-26 Prionics Ag Test strips for the detection of prion proteins
WO2003029813A2 (en) * 2001-09-25 2003-04-10 Prionics Ag Test strips for the detection of prion proteins
US8992854B2 (en) 2002-06-27 2015-03-31 Alere Switzerland Gmbh Assay device for liquid sample
EP1376131A1 (en) * 2002-06-27 2004-01-02 Inverness Medical Switzerland GmbH Assay device for liquid sample
WO2004003559A1 (en) * 2002-06-27 2004-01-08 Inverness Medical Switzerland Gmbh Assay device for liquid sample
AU2003253093B2 (en) * 2002-06-27 2009-02-05 Abbott Rapid Diagnostics International Unlimited Company Assay device for liquid sample
US8454903B2 (en) 2002-06-27 2013-06-04 Alere Switzerland Gmbh Assay device for liquid sample
EP1416275A1 (en) * 2002-10-31 2004-05-06 Oy Reagena Ltd Method for rapid test and control device
WO2004058823A1 (en) * 2002-12-27 2004-07-15 Neobiodigm Co., Ltd Monoclonal antibody against asialo alpha 1-acid glycoprotein, immunochromatographic strip comprising the monoclonal antibody, and method for diagnosing liver diseases using the immunochromatographic strip
CN100384876C (en) * 2002-12-27 2008-04-30 新生命迪吉姆有限公司 Monoclonal antibody against asialo alpha 1-acid glycoprotein, immunochromatographic strip comprising the monoclonal antibody, and method for diagnosing liver diseases using the immunochromatographic s
US7575938B2 (en) 2002-12-27 2009-08-18 Neobiodigm Co., Ltd Method for diagnosing liver diseases
EP1669758A1 (en) * 2004-12-01 2006-06-14 The Jordanian Pharmaceutical Manufacturing Co. Lateral-flow test device providing improved test result validity
WO2006058610A1 (en) * 2004-12-01 2006-06-08 The Jordanian Pharmaceutical Manufacturing Co. Lateral-flow test device providing improved test result validity
JP2008522169A (en) * 2004-12-01 2008-06-26 ザ ヨルダニアン ファーマスーティカル マニュファクチャリング カンパニー Lateral flow test device provides improved test result effectiveness
US7297502B2 (en) * 2004-12-17 2007-11-20 Oakville Hong Kong Company Limited Devices and methods for analyte assays with built-in result reporting using recognizable symbols
US7803636B2 (en) 2004-12-17 2010-09-28 Alere Switzerland Gmbh Devices for analyte assays with built-in result reporting using recognizable symbols
WO2007122403A1 (en) * 2006-04-21 2007-11-01 British Pregnancy Advisory Service Device and method for detection of a pregnancy associated hormone
CN101427137B (en) * 2006-04-21 2012-08-29 英国孕育咨询服务公司 Device and method for detection of a pregnancy associated hormone
US8343439B2 (en) 2006-06-20 2013-01-01 Amic Ab Assay device
WO2007149043A1 (en) * 2006-06-20 2007-12-27 Åmic AB Assay device
CN101506657B (en) * 2006-06-20 2013-11-06 阿米克公司 Assay device
US8759115B2 (en) 2006-06-20 2014-06-24 Johnson & Johnson Ab Assay device
AT512119A1 (en) * 2011-10-24 2013-05-15 Scheuringer Kim TEST DEVICE
AT512119B1 (en) * 2011-10-24 2015-10-15 Scheuringer Kim TEST DEVICE
WO2014134033A1 (en) 2013-02-26 2014-09-04 Astute Medical, Inc. Lateral flow assay with test strip retainer
CN105102980A (en) * 2013-02-26 2015-11-25 阿斯图特医药公司 Lateral flow assay with test strip retainer
US10408828B2 (en) 2013-02-26 2019-09-10 Astute Medical, Inc. Lateral flow assay with test strip retainer
US10670596B2 (en) 2013-02-26 2020-06-02 Astute Medical, Inc. Lateral flow assay with test strip retainer

Also Published As

Publication number Publication date
AU4963897A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
EP0138826B1 (en) Detection of human chorionic gonadotropin
US5110550A (en) Test carrier for the analytical determination of a component of a liquid sample
US7241418B2 (en) Method for immobilizing conjugates in diagnostic tests
EP0465266B1 (en) Complementary visual signal immunoassay
CN101137897B (en) Dual path immunoassay device
US4839297A (en) Test carrier and method for the analytical determination of a component of a body fluid
CA1113841A (en) Test device and method for its use
EP0726462B1 (en) Apparatus and method for conducting a binding assay on an absorbent carrier material
US5939252A (en) Detachable-element assay device
AU619480B2 (en) Lateral flow chromatographic binding assay device
AU643430B2 (en) Solid-phase analytical device
WO1998022824A1 (en) Immunochromatography test strips
EP1202059B1 (en) Biosensor
US8709826B2 (en) Analyte assaying by means of immunochromatography with lateral migration
US20010005585A1 (en) Enzyme-labeled immunoassay and device therefor
US5474902A (en) Semi-permeable capillary assay device
US5573921A (en) Immunochemical displacement for determining an analyte
JP2000506277A (en) Method and test strip for measuring an analyte
JPH01314967A (en) Apparatus and method for immunoassay
US5223436A (en) Test carrier for the analytical determination of a component of a liquid sample
US20080020482A1 (en) Assay Devices
EP1281965B1 (en) Method of measurement in chromatography
US4990442A (en) Assay for an analyte on a solid porous support
EP1566640A1 (en) Sampling device, the method and use thereof
JPH02261395A (en) Quantitative chromatography and apparatus thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA